Homology has a management team with a successful track record of discovering, developing and commercializing therapeutics with a focus on rare diseases. Homology believes its initial clinical data and ...
BEDFORD, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the peer-reviewed publication of data showing that AAVHSC16, one ...
BEDFORD, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the presentation of preclinical data that supports the targeted, ...
BEDFORD, Mass., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that it has initiated the Phase 1 trial for HMI-203, a one-time, ...
Homology Medicines is now able to enroll patients in its HMI-102 gene therapy trial—but is choosing not to. Having persuaded the FDA to lift the clinical hold in June, the biotech has now paused ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A three-year-old biotech backed ...
The field of human genetics is discovering disease-causing mutations at a rapid pace. These mutations drive thousands of rare, debilitating and fatal disorders. While some treatments are available to ...
Homology Medicines is adding an immunosuppressive regimen to a phase 1/2 trial for its phenylketonuria gene therapy, hoping to quell FDA concerns that triggered a clinical hold in February. The agency ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results